RxDoctor Payments Data

Benny Sanchez, MD

Pain Medicine · The Woodlands, TXNPI 1801892153

Payments from drug & device makers

$5,055in general payments, 2019–2025

Across 302 payments — averaging $16.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Redhill Biopharma Inc.$1K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
  • Collegium Pharmaceutical, Inc.$618
  • Daiichi Sankyo Inc.$615
  • Biodelivery Sciences International, Inc.$445
  • Pfizer$287
  • plus $621 from 8 others

What the payments were for

  • Speaking & faculty fees$83016%
  • Food & beverage$4,22584%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,055 in reported general payments places this provider in the 55th percentile of 583 pain medicine providers in Texas.

See all pain medicine providers in Texas

Medicare billing

Part B allowed, 2024
$30,713
Medicare patients
40
Services billed
228

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RelistorMethylnaltrexone Bromide338$835,694
Xtampza ErOxycodone Myristate429$287,981
ZtlidoLidocaine99$58,768
MovantikNaloxegol Oxalate143$56,977
BelbucaBuprenorphine Hcl71$47,043
UbrelvyUbrogepant25$46,502
Buprenorphine221$46,470
QuliptaAtogepant22$26,864
Hysingla ErHydrocodone Bitartrate38$23,246
OxycontinOxycodone Hcl23$18,252
Diclofenac Sodium21$17,679
Morphine Sulfate ErMorphine Sulfate452$14,882
Gabapentin ErGabapentin33$11,057
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen294$9,177
Pregabalin425$9,146

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor$1,194$835,694338 claims
Collegium Pharmaceutical, Inc.Xtampza Er, Belbuca$618$335,023500 claims
AbbVieUbrelvy, Qulipta$114$73,36547 claims
Scilex Pharmaceuticals Inc.Ztlido$118$58,76899 claims
Redhill Biopharma Inc.Movantik$1,276$56,977143 claims
Shionogi IncSymproic$70$7,66317 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 583 pain medicine providers in Texas.

Other pain medicine in The Woodlands

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →